Genprex, Inc. Announces 1-for-22 Reverse Stock Split; Nasdaq Listing Risk, Clinical Updates

What Happened
Genprex, Inc. (GNPX) filed an 8-K reporting that it will effect a one-for-twenty-two (1:22) reverse stock split of its common stock at 12:01 a.m. ET on July 16, 2026. The Company also disclosed receipt of a Nasdaq delisting notice dated June 10, 2026 for failure to meet the $1.00 minimum bid price; Genprex has requested a hearing (which stays delisting) and is using the reverse split as part of its plan to regain compliance. The filing also furnished an investor presentation and provided updates on its Acclaim clinical programs (Acclaim-1 and Acclaim-3) and biomarker work with MD Anderson.

Key Details

• Reverse Stock Split: 1-for-22 effective July 16, 2026 (12:01 a.m. ET); trading symbol remains GNPX; new CUSIP 372446-401.
• Share count estimate: ~11,108,577 shares outstanding as of July 13, 2026 → estimated ~504,936 shares outstanding post-split (before rounding and any subsequent issuances). Fractional shares will be rounded up to whole shares.
• Nasdaq compliance: Received delisting notice (June 10, 2026) for failing to meet Nasdaq Rule 5550(a)(2) $1.00 bid-price requirement; Company requested a hearing and must show a $1.00 closing bid for 10 consecutive business days (subject to Panel discretion).
• Clinical/regulatory updates: Acclaim-1 (REQORSA + Tagrisso) Phase 2a enrolling; Acclaim-3 (REQORSA + Tecentriq) Phase 2 expansion enrolling ~50 patients at ~10–15 U.S. sites with an interim futility analysis after 25 patients (interim expected H1 2027); Acclaim-1 and Acclaim-3 have FDA Fast Track designation and Acclaim-3 has Orphan Drug designation. Biomarker work with MD Anderson identified TROP-2 (high expression) and PTEN (low expression) as potential predictors of REQORSA response; ASCO 2026 abstract published.

Why It Matters
The reverse stock split is intended to help Genprex meet Nasdaq’s $1.00 minimum bid-price requirement and avoid delisting, but there is no guarantee it will achieve or sustain compliance. For investors, a reverse split changes share count and can reduce liquidity; market capitalization may decline if post-split price falls or trading volume weakens. Separately, clinical progress (including favorable early Acclaim-1 outcomes, Fast Track and Orphan Drug designations, and emerging biomarker data) are material to long-term value but do not remove regulatory, clinical or commercial risks. Investors should weigh the near-term listing risk and potential liquidity impacts alongside the company’s clinical development milestones.